Stock Analiz

Beam Therapeutics Inc. (BEAM) financials: revenue, earnings and cash flow

Fiscal 2019–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Beam Therapeutics’s revenue went from $18000 in fiscal 2019 to $140M in fiscal 2025, growth of about 345.0% a year.

Net income in fiscal 2025 was -$80M, a net margin of -57.2%; the best year in this period was 2019 with -$78M.

Over the twelve months to September 30, 2026, revenue was $147M and net income -$108M.

Free cash flow was -$360M in fiscal 2025 and positive in 0 of the 7 years shown.

The diluted share count rose 1426% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2019: $1800020192020: $2400020202021: $52M20212022: $61M20222023: $378M20232024: $64M20242025: $140M2025$140M
Net income
2019: -$78M20192020: -$195M20202021: -$371M20212022: -$289M20222023: -$133M20232024: -$377M20242025: -$80M2025-$80M
Free cash flow
2019: -$85M20192020: -$112M20202021: -$113M20212022: -$26M20222023: -$183M20232024: -$356M20242025: -$360M2025-$360M
EPS (diluted)
2019: $-14.0520192020: $-4.1920202021: $-5.7720212022: $-4.1320222023: $-1.7220232024: $-4.5820242025: $-0.812025$-0.81

Income statement

Fiscal yearTTM2025202420232022202120202019
Revenue$147M$140M$64M$378M$61M$52M$24000$18000
Gross profit————————
Operating income-$393M-$384M-$416M-$176M-$338M-$392M-$133M-$75M
Net income-$108M-$80M-$377M-$133M-$289M-$371M-$195M-$78M
EPS (diluted)$-0.87$-0.81$-4.58$-1.72$-4.13$-5.77$-4.19$-14.05
R&D$409M$410M$368M$437M$312M$387M$103M$55M
Revenue growth—+120.0%−83.2%+520.0%+17.5%+215900.0%+33.3%—

Cash flow

Fiscal yearTTM2025202420232022202120202019
Operating cash flow-$389M-$345M-$347M-$149M$23M-$66M-$96M-$72M
Capital spending-$10M-$15M-$9M-$34M-$49M-$47M-$16M-$13M
Free cash flow-$398M-$360M-$356M-$183M-$26M-$113M-$112M-$85M
Dividends paid—$0$0$0$0$0$0$0
Buybacks————————
Stock-based pay$77M$94M$121M$99M$84M$44M$15M$7M

Balance sheet

Fiscal yearTTM2025202420232022202120202019
Cash—$1.2B$851M$436M$233M$560M$300M$92M
Debt—$154M$161M$173M$179M$142M$100M$26M
Equity—$1.2B$734M$981M$733M$827M$246M-$201M
Total assets—$1.5B$1.1B$1.5B$1.3B$1.5B$452M$156M
Shares (diluted)105M99M82M77M70M64M47M6M

Margins and returns

Fiscal yearTTM2025202420232022202120202019
Gross margin————————
Operating margin-267.7%-274.6%-654.2%-46.7%-555.6%-757.0%-553200.0%-417500.0%
Net margin-73.9%-57.2%-593.1%-35.1%-474.5%-714.9%-810800.0%-435100.0%
FCF margin-271.6%-257.6%-560.8%-48.4%-43.4%-218.1%-467100.0%-469600.0%
ROIC—-27.6%-36.7%-12.1%-29.3%-40.5%-38.4%—
ROE—-6.5%-51.4%-13.5%-39.4%-44.8%-79.2%39.0%

Frequently asked questions

What is Beam Therapeutics’s annual revenue?

$140M in fiscal 2025 and $147M over the twelve months to September 30, 2026.

How much profit does Beam Therapeutics make?

Net income was -$80M in fiscal 2025 (net margin -57.2%).

Is Beam Therapeutics’s revenue growing?

Yes: revenue rose 120.0% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.